glp 1 compound ending New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Moves to Close a

Inform the TSA officer that you are carrying injectable medication

1013 Its antimelanogenic properties result from a variety of mechanisms including stimulation of pheomelanin synthesis rather than darker eumelanin, its antioxidant effects, 14 and interference with intracellular trafficking of melanogenic enzymes

The picture is not as simple as "semaglutide causes blood clots." It is more accurate to say that semaglutide appears to shift certain cardiovascular risks in different directions simultaneously

If ongoing trials continue to deliver positive results, triple agonist therapies for diabetes may represent the next major evolution in treating obesity, type 2 diabetes, and related metabolic diseases